We have a portfolio of leukaemia clinical trials that span AML, childhood ALL, CLL, CML and CMML.
We are funding trials that looking at new treatments for AML, including a new monoclonal antibody that specifically targets a protein on AML cells. Research is taking place to test new drug combinations as quickly as possible to find potential new treatments for older people with AML who may not be able to tolerate standard chemotherapies and stem cell transplants. And we want to prevent people from relapsing after stem cell transplants by finding ways to make this procedure more effective.
We are supporting the UKALL 2011 trial, that aims to find the optimal combination of standard drugs that effectively treats ALL, but with reduced side effects.
For people with CLL, we have trials that are testing new biological treatments, and in different combinations. Researchers are also looking for treatments that will slow down the disease in its early stages, so we can prevent progression and the need for strong drugs.
We are supporting a trial called DESTINY, that wants to find out if people who have CML and who are doing well on their TKI can safely reduce their TKI dose, or even come off it altogether. We are also running a trial that specifically wants to improve the outlook for people who are doing less well, and have progressed to the more advance stage of CML.
And for rarer forms of leukaemia, such as hronic myelomonocytic leukaemia (CMML), we are looking at a targeted drug called tefinostat, which could offer a less harsh treatment option than standard chemotherapy.